Experienced in Low Sodium Level

Dr. Amy E. Schell

Internal Medicine
St Lukes Clinic-Treasure Valley LLC
610 W Hays St, 
Boise, ID 
Accepting New Patients
Experienced in Low Sodium Level
St Lukes Clinic-Treasure Valley LLC
610 W Hays St, 
Boise, ID 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Schell is a primary care provider, practicing in Internal Medicine in Boise, Idaho. Dr. Schell is rated as an Experienced provider by MediFind in the treatment of Low Sodium Level. Her top areas of expertise are Hypothyroidism, Melorheostosis with Osteopoikilosis, Melorheostosis, Osteopenia, and Endoscopy. Dr. Schell is currently accepting new patients.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in ID
Hospital Affiliations
St Luke's Elmore Medical Center
St Luke's Nampa Medical Center
Saint Alphonsus Regional Medical Center
St Luke's Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

ST LUKES CLINIC-TREASURE VALLEY LLC
610 W Hays St, Boise, ID 83702
Other Locations
ST LUKES CLINIC-TREASURE VALLEY LLC
701 E Parkcenter Blvd, Boise, ID 83706

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry
Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry
Enrollment Status: Active_not_recruiting
Publish Date: June 19, 2025
Intervention Type: Other, Device
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
Inspire® Upper Airway Stimulation System (UAS): Post-Approval Study Protocol Number 2014-001
Inspire® Upper Airway Stimulation System (UAS): Post-Approval Study Protocol Number 2014-001
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 9 Less Clinical Trials

12 Total Publications

A Programming Algorithm for Optimizing Hypoglossal Nerve Stimulator Respiratory Entrainment.
A Programming Algorithm for Optimizing Hypoglossal Nerve Stimulator Respiratory Entrainment.
Journal: The Laryngoscope
Published: July 22, 2024
Similar Doctors
Advanced in Low Sodium Level
Dr. Leslie J. Stubbs
Internal Medicine
Advanced in Low Sodium Level
Dr. Leslie J. Stubbs
Internal Medicine

St Lukes Clinic-Treasure Valley LLC

701 E Parkcenter Blvd, 
Boise, ID 
 (2.3 miles away)
208-381-6500
Languages Spoken:
English, Bosnian, Spanish
See accepted insurances
Accepting New Patients

Leslie Stubbs is a primary care provider, practicing in Internal Medicine in Boise, Idaho. Dr. Stubbs is rated as an Advanced provider by MediFind in the treatment of Low Sodium Level. Her top areas of expertise are Low Sodium Level, Hypothyroidism, Type 2 Diabetes (T2D), and High Cholesterol. Dr. Stubbs is currently accepting new patients.

Experienced in Low Sodium Level
Dr. Mark L. Holbrook
Internal Medicine
Experienced in Low Sodium Level
Dr. Mark L. Holbrook
Internal Medicine

St Lukes Clinic-Treasure Valley LLC

608 W Hays St, 
Boise, ID 
 (0.1 miles away)
208-381-5970
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Holbrook is a primary care provider, practicing in Internal Medicine in Boise, Idaho. Dr. Holbrook is rated as an Advanced provider by MediFind in the treatment of Low Sodium Level. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Type 2 Diabetes (T2D). Dr. Holbrook is currently accepting new patients.

Experienced in Low Sodium Level
Dr. Mark D. Christenson
Internal Medicine
Experienced in Low Sodium Level
Dr. Mark D. Christenson
Internal Medicine

St Lukes Clinic-Treasure Valley LLC

1210 Nw 16th St, 
Fruitland, ID 
 (46.1 miles away)
208-452-8600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Christenson is a primary care provider, practicing in Internal Medicine in Fruitland, Idaho. Dr. Christenson is rated as an Advanced provider by MediFind in the treatment of Low Sodium Level. His top areas of expertise are Otitis, Type 2 Diabetes (T2D), Gastroesophageal Reflux Disease (GERD), and Hypertension. Dr. Christenson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schell's expertise for a condition
ConditionClose
      View All 76 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile